- Home
- EVAX vs DXST Comparison
EVAX vs DXST Comparison
Compare EVAX & DXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- DXST
- Stock Information
- Founded
- EVAX 2008
- DXST 2011
- Country
- EVAX Denmark
- DXST China
- Employees
- EVAX N/A
- DXST N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- DXST
- Sector
- EVAX Health Care
- DXST
- Exchange
- EVAX Nasdaq
- DXST NYSE
- Market Cap
- EVAX 16.3M
- DXST 18.7M
- IPO Year
- EVAX 2021
- DXST 2025
- Fundamental
- Price
- EVAX $1.49
- DXST $1.04
- Analyst Decision
- EVAX Strong Buy
- DXST
- Analyst Count
- EVAX 2
- DXST 0
- Target Price
- EVAX $10.00
- DXST N/A
- AVG Volume (30 Days)
- EVAX 76.2K
- DXST 35.0K
- Earning Date
- EVAX 05-27-2025
- DXST 01-01-0001
- Dividend Yield
- EVAX N/A
- DXST N/A
- EPS Growth
- EVAX N/A
- DXST 13.11
- EPS
- EVAX N/A
- DXST 0.14
- Revenue
- EVAX $3,344,000.00
- DXST $11,542,292.00
- Revenue This Year
- EVAX $102.45
- DXST N/A
- Revenue Next Year
- EVAX $100.30
- DXST N/A
- P/E Ratio
- EVAX N/A
- DXST $7.72
- Revenue Growth
- EVAX 4480.82
- DXST 22.18
- 52 Week Low
- EVAX $1.20
- DXST $0.85
- 52 Week High
- EVAX $21.80
- DXST $5.74
- Technical
- Relative Strength Index (RSI)
- EVAX 43.19
- DXST N/A
- Support Level
- EVAX $1.20
- DXST N/A
- Resistance Level
- EVAX $1.46
- DXST N/A
- Average True Range (ATR)
- EVAX 0.13
- DXST 0.00
- MACD
- EVAX 0.03
- DXST 0.00
- Stochastic Oscillator
- EVAX 59.18
- DXST 0.00
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.